Biosimilars for Chronic Inflammation Management

Roy M. Fleischmann, MD and Joel M. Gelfand, MD, MSCE, FAAD define the terms biologic and biosimilars and discuss how they are developed.

Drs Roy M. Fleischmann and Joel M. Gelfand discuss differences between biosimilars and reference products.

An expert rheumatologist and dermatologist discuss differences between biosimilars and generic drugs.

Roy M. Fleischmann, MD, and Joel M. Gelfand, MD, MSCE, FAAD, define the terms associated with biosimilars, including the interchangeable designation.

Drs Roy M. Fleischmann and Joel M. Gelfand explain extrapolation and how it will change the field of dermatology and rheumatology.

Drs Roy M. Fleischmann and Joel M. Gelfand define interchangeability status and discuss its impact on the field of dermatology and rheumatology.

Expert rheumatologist and dermatologist, Drs Roy M. Fleischmann and Joel M. Gelfand discuss unmet needs in biosimilars.

Roy M. Fleischmann, MD, and Joel M. Gelfand, MD, MSCE, FAAD, discuss the impact of biosimilars on payers, health care systems, and patients.

Drs Roy M. Fleischmann and Joel M. Gelfand discuss the roles of biosimilars and how to assess efficacy once a patient is switched to a biosimilar.

Expert rheumatologist and dermatologist, Drs Roy M. Fleischmann and Joel M. Gelfand, discuss the impact of switching patients to biosimilars.

An expert rheumatologist and a dermatologist discuss challenges to bringing biosimilars to the United States.

Roy M. Fleischmann, MD, and Joel M. Gelfand, MD, MSCE, FAAD, address the importance of clinician confidence in biosimilars.

Drs Roy M. Fleischmann and Joel M. Gelfand discuss addressing patient concerns with biosimilars and provide take-home messages to clinicians utilizing biosimilars.